description
Dox-NP™ (Liposomal Encapsulated Doxorubicin), frozen liposomal suspension (buffer - 10% w/w sucrose, 10 mM histidine ~pH 6.5)
assay
>99% (HPLC/MS)
form
dispersion
packaging
pkg of 1 × 5 mL (300115S-1EA)
manufacturer/tradename
Avanti Research™ - A Croda Brand
application(s)
advanced drug delivery
shipped in
dry ice
storage temp.
−20°C
正在寻找类似产品? 访问 产品对比指南
General description
Formulation: A Pegylated, long-circulating liposomal formulation with doxorubicin entrapped within an ammonium sulfate core via remote-loading. All unencapsulated was removed to yield a completely liposomal doxorubicin product. Liposomes are stored frozen for a longer shelf life.
Application
Dox-NP™(5mL vial) has been used as a sample to study its characteristics by asymmetrical-flow field flow fractionation (MD-AF4). It may also be used as an intravenous (i.v.) injection in flank or orthotopic animal models of cancer.
Packaging
10 mL amber serum vial (300115S-1EA)
Legal Information
Avanti Research is a trademark of Avanti Polar Lipids, LLC
Dox-NP is a trademark of Avanti Polar Lipids, LLC
存储类别
12 - Non Combustible Liquids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
新产品
此项目有
Physical characterization of liposomal drug formulations using multi-detector asymmetrical-flow field flow fractionation
Parot J, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society (2020)
J Parot et al.
Journal of controlled release : official journal of the Controlled Release Society, 320, 495-510 (2020-02-01)
Liposomal formulations for the treatment of cancer and other diseases are the most common form of nanotechnology enabled pharmaceuticals (NEPs) submitted for market approval and in clinical application today. The accurate characterization of their physical-chemical properties is a key requirement;
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持